A review and update on melanocyte stimulating hormone therapy: afamelanotide.
Copyright policy )A review and update on melanocyte stimulating hormone therapy: afamelanotide.
Afamelanotide ([Nle4-D-Phe7]-alpha-MSH) is an analog of alpha-melanocyte stimulating hormone given as a subcutaneous injection. Afamelanotide is currently undergoing phase II and III trials in Europe and the US for skin diseases including vitiligo, erythropoietic protoporphyria, polymorphic light eruption and prevention of actinic keratoses in organ transplant recipients. Unregulated analogs and chemicals are being sold online ahead of formal approval. A number of counterfeit chemicals, 'Melanotans' are being sold for tanning purposes. Currently, afamelanotide is already on the market in Italy and Switzerland for patients with erythropoietic protoporphyria. This paper will review the current literature on this promising compound.
- Larkin Community Hospital United States
Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Protoporphyria, Erythropoietic, alpha-MSH, Injections, Subcutaneous, Humans, Skin Diseases
Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Protoporphyria, Erythropoietic, alpha-MSH, Injections, Subcutaneous, Humans, Skin Diseases
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).27 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!